Partners Vi, L.P.Blair Jame... Net Worth

The estimated Net Worth of Partners Vi, L.P.Blair Jame... is at least $3.44 Million dollars as of 5 August 2014. Partners Jame owns over 419,744 units of Marinus Pharmaceuticals Inc stock worth over $3,442,872 and over the last 11 years Partners sold MRNS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Jame MRNS stock SEC Form 4 insiders trading

Partners has made over 2 trades of the Marinus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Partners bought 419,744 units of MRNS stock worth $3,357,952 on 5 August 2014.

The largest trade Partners's ever made was buying 419,744 units of Marinus Pharmaceuticals Inc stock on 5 August 2014 worth over $3,357,952. On average, Partners trades about 180,299 units every 32 days since 2014. As of 5 August 2014 Partners still owns at least 2,476,886 units of Marinus Pharmaceuticals Inc stock.

You can see the complete history of Partners Jame stock trades at the bottom of the page.

Insiders trading at Marinus Pharmaceuticals Inc

Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... und Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.

What does Marinus Pharmaceuticals Inc do?

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides

Complete history of Partners Jame stock trades at Aldeyra Therapeutics Inc und Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc executives and stock owners

Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Scott Braunstein,
  President, Chief Executive Officer, Director
• Edward Smith,
  Chief Financial Officer
• Dr. Scott N. Braunstein M.D.,
  CEO, Pres & Director
• Dr. Scott Braunstein,
  CEO, Pres & Director
• Edward F. Smith CPA,
  Consultant
• Dr. Joseph Hulihan M.D.,
  Chief Medical Officer
• Joseph Hulihan,
  Chief Medical Officer
• Timothy Mayleben,
  Independent Director
• Nicole Vitullo,
  Chairman of the Board
• Michael Dougherty,
  Independent Director
• Seth Fischer,
  Independent Director
• Enrique Carrazana,
  Independent Director
• Elan Ezickson,
  Independent Director
• Charles Austin,
  Director
• Sasha Damouni Ellis,
  Vice President of Investor Relations
• Martha Manning,
  Vice President, General Counsel, Secretary
• Dr. Kimberly A. McCormick Pharm.D., PharmD,
  Sr. VP of Regulatory Affairs
• Sonya Weigle,
  VP of HR
• Lisa Lejuwaan,
  VP of Sales
• Steven E. Pfanstiel C.M.A., M.B.A.,
  CFO & Treasurer
• Dr. Kimberly A. McCormick,
  VP of Regulatory Affairs
• Christy Shafer,
  Chief Commercial Officer
• Dr. Alex Aimetti,
  Head of Scientific Affairs
• Rose McKinley,
  VP of HR & Organizational Devel.
• Thomas J. Lyons,
  VP of Corp., Bus. Devel. & Commercial Planning
• Martha E. Manning,
  VP, Gen. Counsel & Sec.
• Stephen M Bloch,
  Director
• Christopher Michael Cashman,
  PRESIDENT AND CEO
• Jay Shepard,
  Director
• Anand Sofinnova Venture Par...,
  
• Anand Mehra,
  Director
• Gail M Farfel,
  Chief Clinical Dev & Reg
• Vii L P Canaan Partners Vii...,
  
• Albena Patroneva,
  Chief Medical Officer
• Masuoka K. Lorianne,
  Chief Medical Officer
• Capital Life Sciences Inves...,
  
• Christine Berni Silverstein,
  
• Sara Nochur,
  
• Anton Gopka,
  Director
• Partners Vi, L.P.Blair Jame...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Marvin Johnson,
  
• Santiago Arroyo,
  Director
• Sarah B. Noonberg,
  
• Christina Shafer,
  CHIEF COMMERCIAL OFFICER
• Steven Pfanstiel,
  CFO AND COO